Elan aims to complete Zonegran deal in April

Pharmaceutical firm Elan has sold its interests in anti-epileptic drug Zonegran to Eisai for $130m (€106.41m) if the deal is finalised by the end of April.

If the deal is concluded after April 30, Elan will receive $110m (€90.04m) for the US rights, $25m (€20.46m) for the European rights and additional deferred payments on net sales if certain conditions are met.